Cellistic

Cellistic is proud to announce our process development and manufacturing agreement with BrightPath Bio to advance their pioneering allogeneic CAR-iNKT cell therapy platform, utilizing iPSC-derived NKT cells for clinical trials targeting multiple myeloma. Through this #partnership, we will leverage our advanced iPSC technology and state-of-the-art Echo® 3D bioreactor platform to enable GMP-compliant, clinical-scale production, addressing key challenges in cell therapy manufacturing while ensuring the functionality of these specialized cells. This collaboration marks a significant step toward enhancing innovation in oncology and making effective cell therapies more accessible to patients. Read the full #PressRelease ➡️ https://hubs.ly/Q02_zSrq0 #Cellistic #iPSC #CellTherapy #Oncology #ClinicalTrials

🦠 How can induced pluripotent stem cells (iPSCs) transform T cell therapies? Research by Quell Therapeutics and Cellistic analyzes the development and characterization of iPSC-derived regulatory T cells and explores their potential in advancing immunotherapy and improving treatment strategies. 🔗Discover the scientific insights and implications of this research in our joint poster: https://hubs.ly/Q02-WH2J0 #Cellistic #iPSCs #CellTherapies #TCells

At Cellistic, we’re not just equipped with a certified GMP facility for manufacturing iPSC-based allogeneic cell therapies — we’ve also developed Echo™, our proprietary technology platform. Combined with robust processes, Echo™ ensures scalability, consistency, and high quality. Our MSAT Director, Anne-Sophie Lebrun shares a 2-minute insight into how we address the unique challenges of scaling iPSC-based therapies. Curious to learn more about Echo™ and and our scale-up capabilities ? 👉 https://hubs.ly/Q02ZMC-R0

Giving a second life to scientific equipment ♻️🧪 After repurposing its certified GMP manufacturing facility exclusively for #iPSCs, Cellistic is happy to donate equipment no longer in use to UNamur - Futur étudiant. 'New' freezers, CO₂ incubators, microscopes, and chemical storage cabinets now equip the Unité de Recherche en Physiologie Moléculaire (URPhyM), the Unité de Recherche en Biologie Environnementale et Évolutive (URBE), and the Integrated Veterinary Research Unit (URVI) at this Walloon-based university in Belgium, continuing to support groundbreaking research and innovation. Special thanks to Cellistic's Procurement and Supply Chain teams for their seamless coordination with the University of Namur, and a shoutout to the team from Genné who braved the snow to deliverthis scientific equipment to its new home! #Cellistic #AdvancingTherapies

#PressRelease Cellistic® is proud to announce the successful certification of its first GMP facility dedicated to iPSC-based allogeneic cell therapies. This milestone, certified by the Belgian FAMHP - Federal Agency for Medicines and Health Products operating under European Medicines Agency guidelines, reflects Cellistic's mission to pave the way to accessible cell therapies, making treatment more available to patients. 🌟 Read the full press release: https://hubs.ly/Q02Z1NYB0 #Cellistic #CellTherapy #Allogeneic #iPSC #BiotechInnovation #GMPManufacturing

At the recent Alliance for Regenerative Medicine's Meeting on the Mesa in Phoenix, attendees were the first to hear from Cellistics CEO Gustavo Mahler about an exciting development: our 'Allo Chassis' cell line, featuring the most prevalent gene edits used to prevent adverse immune reactions, will be available starting January 2025. This marks a major milestone in advancing cell therapy, with ready-to-use cell lines incorporating key gene edits that streamline the path to final product release. 🔥More to come in #January2025 – stay tuned! https://hubs.ly/Q02YSd3_0 #Cellistic #celltherapy #iPSC #offtheshelfcelllines #geneedits #geneediting

Have you read John Barlow’s expert insights on how Cellistic is tackling the complexities of characterizing cell-based medicines? As pioneers in iPSC-based therapies, we’re advancing analytical solutions to ensure every treatment is safe, consistent, and effective. 🔬In our latest article, our Analytical Development Director presents the unique challenges of batch consistency, potency assays, and critical quality attributes—and Cellistic's approach to addressing these challenges. Read the full article: https://hubs.ly/Q02YjMXh0 #CellTherapy #iPSC #Biotechnology #Cellistic #QualityControl

🎥Join Cellistic Webinar🎓 From iPSCs to Functional NK Cell Therapy with Cellistic – Client Journey October 22nd 17:30 CET/11;30 AM EST/8:30 AM PST Join Jonas Mortensen, Cellistic's Chief Commercial Officer, as he guides you through the evolving cell therapy landscape. Discover the advantages of transitioning to iPSC-based allogeneic cell therapies, a pivotal shift in modern healthcare. Our experts, Suzanne Snellenberg, VP cell line Development and Anne-Sophie Lebrun, MSAT Director will provide an in-depth look at your product journey: - Pulse Platform: Developing your iPS cell line - Echo Platform: Differentiating into functional NK cells You'll see how these elements seamlessly come together to shape your unique journey. Interactive Q&A session with dedicated time for audience questions, ensuring you get the insights you need. Registration link https://hubs.ly/Q02Tn2nJ0

Our VP of BD in Europe and APAC Peter Jaehn, Dr. had the opportunity to present at Center for IPS Cell Research and Application. Japan is very advanced within iPSC with the infant of Yamanaka receiving the nobel price in 2012 for his discovery of reprogramming factors enabling iPSC. At Cellistic we have worked with iPSC for over a decade which enable cell therapy companies with experience and speed using our Pulse and Echo platform to ensure future scalability of your cell therapy candidates. #celltherapy

☀️ Good morning, #CGMesa24 attendees! Day 1 of the conference is here, and we can’t wait to connect with everyone this week. Don’t miss our CEO, Gustavo Mahler, presenting on Cellistic Vision and iPSC technology today at 9:30 in FLW Ballroom E. Click below to schedule a meeting with us! https://hubs.ly/Q02SlFY40 #cellandgenetherapy #meetingonthemesa #cellistic #celltherapy #genetherapy